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Abstract With an incidence of approximately 350 in
100,000, stroke is the third leading cause of death and a
major cause of disability in industrialized countries. At
present, although progress has been made in understanding
the molecular pathways that lead to ischemic cell death, the
current clinical treatments remain poorly eVective. There is
mounting evidence that inXammation plays an important
role in cerebral ischemia. Experimentally and clinically,
brain response to ischemic injury is associated with an
acute and prolonged inXammatory process characterized by
the activation of resident glial cells, production of inXam-
matory cytokines as well as leukocyte and monocyte inWl-
tration in the brain, events that may contribute to ischemic
brain injury and aVect brain recovery and plasticity. How-
ever, whether the post-ischemic inXammatory response is
deleterious or beneWcial to brain recovery is presently a
matter of debate and controversies. Here, we summarize the
current knowledge on the molecular mechanisms underly-
ing post-ischemic neuronal plasticity and the potential role
of inXammation in regenerative processes and functional
recovery after stroke. Furthermore, because of the dynamic
nature of the brain inXammatory response, we highlight the
importance of the development of novel experimental
approaches such as real-time imaging. Finally, we discuss
the novel transgenic reporter mice models that have
allowed us to visualize and to analyze the processes such as
neuroinXammation and neuronal repair from the ischemic
brains of live animals.
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Introduction
After heart disease and cancer, with an incidence of approx-
imately 350 in 100,000, stroke is the third leading cause of
death and a major cause of disability in industrialized coun-
tries [34, 87]. In the last decade, according to the American
Heart Association, the mortality rate from stroke has
declined by approximately 12%; however, the total number
of stroke cases is not in decline and may actually be rising
[118]. Moreover, stroke represents a major social burden
for society. In fact, only a minority of stroke patients will
completely recover and, in most instances, ischemic brain
injuries are associated with mild to severe permanent neu-
rological deWcits. These deWcits can include partial paraly-
sis, diYculties with memory, thinking, language and
movements. In practice, the term “stroke” refers to an
umbrella of conditions caused by the occlusion or hemor-
rhage of blood vessel supplying the brain [8, 34, 87]. In all
instances, stroke ultimately involves dysfunction and death
of brain cells and neurological deWcits that reXect the loca-
tion and size of the compromised brain area. At present,
although progress has been made in understanding the
molecular pathways that lead to ischemic cell death, the
current clinical treatments remain poorly eVective [34, 87].
The only approved therapy is thrombolysis induced by
intravenous administration of recombinant tissue plasmino-
gen activator (tPA); however, because of a short therapeutic
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from this treatment. According to a current view, treatment
of stroke is suboptimal without a combination of clot-lysing
therapy with neuroprotection and/or pro-regeneration treat-
ments [45, 46, 87]. Therefore, the quest for novel and more
eVective therapeutic strategies remains a priority. An addi-
tional problem, in designing eVective therapeutic strategies
for stroke, may lay in the fact that most targets, such as
inXammation, may have a dual and possibly time-depen-
dent role (Janus eVect) in the complex pathological cascade
of events associated with the brain response to ischemic
injury [39, 45, 75].
In this review, we give a short overview of the patho-
physiological events involved in the evolution of ischemic
brain damage, and the potential role of inXammation in
regenerative processes and functional recovery after stroke.
Furthermore, because of the dynamic and very complex
nature of the brain inXammatory response, we will highlight
the importance for development of novel experimental
approaches to study neuroinXammation, such as real-time
imaging. Finally, we will discuss the novel transgenic
reporter mouse models for in vivo biophotonic/biolumines-
cence imaging of glial responses to ischemic injury. Genera-
tion of these novel model systems has allowed visualization
and analysis of the processes such as neuroinXammation and
repair from the brains of live animals.
Brain response to ischemic injury
Brain ischemic injury is comprised of two major patho-
physiological processes, a loss of oxygen and glucose sup-
ply induced by vascular occlusion is followed by a series of
acute metabolic changes. This consequently causes the col-
lapse of energy-producing processes resulting in the disin-
tegration of cell membranes and neuronal death at the
center/core of infarction. In the center or core of the ische-
mic territory, cell death progresses within minutes as a
result of acute blood Xow deWcits, low ATP levels, ionic
disruption and severe metabolic failures [54, 74]. The
peripheral zones within the Xow-compromised territory,
called the ischemic penumbra, suVer milder early damage
due to a residual perfusion from the collateral blood vessels
[90]. To deWne penumbra in hemodynamic terms, this is the
region where local cerebral blood Xow is reduced to an
intermediate degree, i.e, 20–40% of control values [44]. In
the centre of the ischemic region, cells undergo anoxic
depolarization and they never repolarize, while in the pen-
umbral region, the cells can repolarize at the expense of
further energy consumption and depolarize again in
response to elevated levels of extracellular glutamate and
potassium ions [K+]. Such repetitive depolarizations, called
“peri-infarct depolarizations”, lead to the increased release
of the excitatory neurotransmitter glutamate with ensuing
excitotoxic cell damage [55]. Ultimately, the severity of
functional and structural (irreversible) changes in the brain
caused by ischemia will depend on its degree and duration.
Here it is important to note that the brain response to ische-
mia is not a simple pathological event. It includes the acti-
vation of several pathophysiological pathways that may be
associated simultaneously with the processes of neuronal
death and/or neuroregeneration. As previously suggested
by Dirnagl and colleagues [34], brain damage following
transient or permanent ischemia results from a series of
pathophysiological events that evolve in time and space.
Early pathophysiological events start a few minutes after
stroke and last for several hours. They include acute necro-
sis in the centre of infarction, followed by peri-infarct
depolarizations, excitotoxicity and oxidative stress [34, 87].
Experimental evidence suggests that neurons at the border
of the ischemic territory can survive for many hours, even
days after an ischemic insult [30]. The delayed tissue
response to brain ischemia encompasses processes such as
inXammation and apoptosis. These delayed processes are
initiated several hours after the initial ischemic attack and
may persist for several days even weeks after stroke. At
present, it is not exactly clear how these events may aVect
post stroke recovery and brain regenerative responses.
Brain plasticity and post stroke recovery
In cerebral ischemia, the initial pathological events associ-
ated with direct cell death are followed by the activation of
regenerative processes for days, weeks or even months fol-
lowing initial stroke [27, 138]. After an ischemic attack, a
majority of stroke patients exhibit certain levels of motor
weakness and sensory disturbances; however, over time,
most will show a certain degree of functional recovery [28,
63]. The results of several animal and human studies on
stroke have revealed that post stroke recovery and restora-
tion of function may be explained by brain reorganization
and brain plasticity [63, 82, 126, 129]. As suggested by
Lledo and colleagues [86], brain plasticity refers to the
brain ability to change its structure and function during
maturation, learning, environmental changes and pathol-
ogy. Altogether, brain plasticity ultimately involves all the
mechanisms implicated in the capacity of the brain to adjust
and remodel itself in response to environmental require-
ments, experience, skill acquisition and new challenges
including brain lesions. For example, starting within the
minutes following ischemia, rapid changes are observed in
the number and the length of dendritic spines. Loss of den-
dritic spines observed at the excitatory synapses may reXect
an early adaptive response of vulnerable ischemic neurons
in the peri-infarct region [19, 51]. The initial loss, at the123
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of the dendritic spine synapses and its dynamic and rapidly
changing milieu represents a potential substrate for func-
tional recovery [27]. Loss of function following ischemic
stroke is determined by neuronal death within the center of
the infarcted zone, but also with the dysfunction of the cells
in the hypoperfused areas (penumbra region) surrounding
the ischemic lesion. Additional loss of function in the neu-
roanatomically more remote areas is believed to be due to
loss of connections, some major metabolic changes and
altered neuron transmission [138, 140]. Conversely, the
molecular mechanisms of neuroplasticity that would under-
lie eYcient functional recovery and compensate for a loss
of function should therefore include unmasking the silent
pathways and/or synapses as well as the recruitment of
alternative parallel pathways which would require axonal
sprouting and the formation of new synapses from surviv-
ing neurons. The results of the recent studies by Brown
et al. and Winship and Murphy [19, 139] further conWrm
these views. Taking advantage of an in vivo imaging
approach and the transgenic mouse model expressing YFP
in layer 5 cortical neurons, they demonstrated that the ini-
tial rapid changes in the dendritic response were followed,
at later time points, by functional reorganization and rewir-
ing of surviving neurons several months after initial stroke
[19, 139].
Functional recovery after cerebral ischemia has been
associated with brain plasticity. However, the exact causal
link, the factors that can inXuence plasticity and its tempo-
ral characteristics have not yet been completely established.
To date, most of the research eVorts to enhance spontane-
ous post-injury plasticity and function recovery after stroke
have been oriented towards controlled rehabilitation studies
and enriched environment [17, 64, 100, 101], pharmacolog-
ical and/or indirect electrical and transcranial magnetic
stimulation of the brain, [16, 56] and more recently, cell
based therapies [52, 69]. The targeted research in this direc-
tion has provided us with some promising results; however,
there is a growing line of evidence suggesting that in addi-
tion to previously mentioned approaches, the brain inXam-
matory response to ischemia and glial cells may play an
important role in the modulation of post-ischemic synaptic
plasticity and brain recovery [49, 136].
InXammatory response after stroke: a dual role?
Although for many years, the central nervous system (CNS)
has been considered to be an immune-privileged organ, it is
now well accepted that the immune and the nervous system
are engaged in bi-directional crosstalk [125]. Moreover,
mounting evidence suggest that in the brain as in other
organs, inXammatory cells could participate in tissue
remodeling and reconstruction following injury. Experi-
mentally and clinically, stroke is followed by an acute and
prolonged inXammatory response characterized by the acti-
vation of resident glial cells, the production of inXamma-
tory cytokines, as well as leukocyte and monocyte
inWltration in the brain. These events may contribute to
ischemic brain injury [34, 75, 79, 87]. However, whether
post-ischemic inXammatory responses are deleterious or
beneWcial to brain recovery is presently a matter of debate.
To add to this controversy, in the past few years, several
groups have reported conXicting results on the role of
inXammation and eVects of anti-inXammatory approaches
in cerebral ischemia. For example, elevated levels of IL-6
in the circulation have long been associated with the sever-
ity of stroke [11, 134]. Barone et al. [9] demonstrated that
blocking endogenous TNF signiWcantly reduced infarct
size in rats with the permanent or transient middle cerebral
artery occlusion. A role for IL-1 in the pathogenesis of
ischemic brain damage is supported by increased infarction
resulting from intracerebroventricular injection of this cyto-
kine in rat brain and conversely, neuroprotective eVects of
interleukin-1 receptor antagonist [88, 114, 141]. In addi-
tion, short-term treatments with the antimicrobial/anti-
inXammatory agent minocycline alone or in combination
conferred neuroprotection in experimental stroke [3, 137,
142, 143]. The treatments with nonsteroid anti-inXamma-
tory agents that selectively or non-selectively inhibit cyclo-
oxygenase 2 (COX-2), in some studies, also conferred
neuroprotection in experimental cerebral ischemia [110,
132]. Altogether these results suggest that inXammation
after stroke is detrimental for brain. However, to date, the
role of post-ischemic inXammation and the pro-inXamma-
tory cytokines is cerebral ischemia is not yet completely
elucidated. The study by Clark et al. demonstrated that inf-
arct size and neurological function were not diVerent in ani-
mals deWcient in IL-6 after transient CNS ischemia. This
suggests that IL-6 does not have a direct inXuence on acute
ischemic injury [24]. On the other hand, the results of sev-
eral other studies revealed that the deletion of cytokine and/
or cytokine receptors for TNF and/or IL-6 resulted in a
signiWcantly larger amount of necrotic tissue, higher mor-
tality and poor functional outcome following experimental
ischemia and brain injury [20, 42, 124, 128]. Findings of
Carlson et al. [23], using in vitro conditions also suggested
a possible neuroprotective role of diVerent cytokines. To
add to this confusion, and in contradiction to some previous
results, Hara et al. [50] reported that there was no beneWcial
eVect on temporary focal cerebral ischemia in rats follow-
ing selective inhibition of COX-2. Moreover, treatments
with diVerent classes of COX inhibitors had negative
eVects on the proliferation of neuronal progenitor cells in
dentate gyrus following cerebral ischemia [120, 121].
Finally, recent studies demonstrated beneWcial eVects of123
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colony-stimulating factor (GM-CSF) and macrophage col-
ony stimulating factor (MCSF) in the treatment of experi-
mental cerebral ischemia [79, 122, 127].
The main eVectors of the immune response in the brain
are glial cells, in particular activated microglia. Although, it
is generally believed that the activated microglial cells in
ischemic injury are neurotoxic, the results of several recent
studies revealed, that in certain conditions microglia may
exert neuroprotection [70, 71], be involved in the regulation
of regenerative state and the remodeling of the brain by
producing neurotrophic molecules such as brain-derived
neurotrophic factor (BDNF) [10, 93, 95], insulin growth
factor 1 (IGF-1) [79, 102] and depending on the type of
stimuli, several other growth factors [49]. Moreover, the
studies from Neumann and colleagues using organotypic
hippocampal brain slices exposed to oxygen/glucose depri-
vation (OGD), an in vitro model of stroke, clearly demon-
strated that activated microglial cells can protect neurons
by direct physical contacts [97] and/or by the engulfment of
activated and neurotoxic polymorphonuclear neutrophils
(PMNs) [98]. Altogether, these Wndings further support the
view that the close brain–immune system interactions are
highly relevant for functional outcome after stroke. An
additional interesting point recently revealed by Lai and
Todd [78] is that severity of neuronal injury may in fact
inXuence whether microglia would release toxic or neuro-
protective eVects. However, the ability of glial cells, in par-
ticular, activated microglia, to produce and secrete growth
factors raises the possibility that inXammatory cells may
have a role in tissue remodeling after cerebral ischemia and,
therefore, aVect brain plasticity and functional recovery
after stroke.
InXammatory response, brain plasticity and functional 
recovery after stroke
At present, the complete temporal and spatial dynamics of
post-ischemic inXammatory response is not known. The
recent results suggest that the inXammatory response after
ischemia has a marked chronic component. Namely,
Ekdahl and coworkers [38] reported an increased number
of activated microglial cells up to 16 weeks after 2 h middle
cerebral artery occlusion (MCAO) stroke model in rats.
Using the novel transgenic mouse model recently devel-
oped in our laboratory, we were able to visualize/detect
activated microglial cells several months after moderate
(60 min) MCAO occlusion in mice [26]. Together, these
Wndings suggest that an active post-ischemic inXammatory
response may lasts much longer than initially thought and
may temporally coincide with the processes of post-ische-
mic recovery. This raises the possibility that inXammatory
response after ischemia may play an active role in CNS
regeneration.
Glial cells and trophic factors
Activated glial cells, in particular microglia express and
secrete a broad spectrum of diVerent molecules such as
cytokines, neuronal growth factors, neurotransmitters (glu-
tamate) and diVusible molecules such as NO which are
known to regulate synaptic functions [2, 34, 43, 48, 113,
116]. Microglial cells are the main eVectors of the immune
response following brain injuries and several hours after
stroke, the resident microglial cells become activated, accu-
mulate at the lesion site, in the penumbra region and prolif-
erate. Using a transgenic mouse model for the selective
ablation of proliferating microglial cells, we recently dem-
onstrated that the subset of resident microglial cells in pro-
liferation express and secrete neurotrophic growth factors
such as IGF-1 [79]. Conversely, the ablation of the prolifer-
ating microglial cells was associated with a signiWcant
decrease in IGF-1 levels. The microglial IGF-1 expression
has been also recently reported by Ohtaki et al. [104].Using
a diVerent experimental approach, Imai and colleagues [58]
demonstrated that exogenous transplantation of microglial
cell into ischemic brain resulted with an increase in the lev-
els of BDNF. Finally, that activated and proliferating glial
cells may indeed represent an important source of neutro-
phins in post-ischemic brain has been recently demon-
strated by Tonchev et al. [133]. In their work, the in situ
studies performed on ischemic primate brain revealed that
ischemic injury resulted in a strong up-regulation of trkA
and trkB receptors (NGF and BNDF receptors, respec-
tively), in the pyramidal neurons of ischemic hippocampus,
thus suggesting that activation and proliferation of resident
glial cells following ischemic injury, as a part of the inXam-
matory response, may play an important role in modulation
of brain plasticity via secretion of trophic molecules [133].
Cytokines and brain plasticity
There is substantial evidence demonstrating that activated
microglial cells in response to ischemia have the potential
of releasing several pro-inXammatory cytokines such as
TNF-alpha, IL-1 and IL-6, as well as other potential cyto-
toxic molecules including nitric oxide, reactive oxygen spe-
cies and prostanoids [34, 57, 119]. Cytokines are regulatory
proteins that had been traditionally viewed as immune
modulators. However, experimental evidences suggest that
they play an important role as a neuromodulators following
CNS injuries. The results of several experimental studies
demonstrated that pro-inXammatory cytokines may aVect
synaptic plasticity. The current view is that at low “physio-
logical” levels, cytokines and others immune mediators123
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135]. On the other hand, after injuries such as cerebral
ischemia, the induction and the over-expression of these
molecules that occurs as a part of neuroinXammatory
response may result in the impairment of synaptic plasticity
and the associated neurodegeneration. Earlier studies dem-
onstrated inhibitory eVects of IL-1 on the hippocampal
long-term potentiation (LTP) [67]. The exact mechanisms
of the inhibitory eVects of IL-1 on synaptic plasticity are
not completely elucidated; however, in vitro studies per-
formed on pharmacologically isolated NMDA receptors
revealed that administration of IL-1 was associated with
signiWcant decrease in NMDA receptor excitatory post-syn-
aptic potentials [14, 41]. Similar eVects with regard to LTP
were observed in the transgenic mouse model over-express-
ing IL-6. Cerebral over-expression of IL-6 in GFAP-IL6
transgenic mouse models was associated with signiWcant
reduction of LTP in the hippocampus [15]. Conversely, the
experiment performed on freely moving rats demonstrated
that blockade of endogenous IL-6 using a neutralizing anti-
IL6 antibody was associated with marked prolongation of
LTP and signiWcant improvement in long-term memory [7].
Surprisingly, the eVects of the pro-inXammatory cytokine
TNF- on synaptic plasticity are somehow less clear. TNF-
is considered to be a crucial pro-inXammatory cytokine
involved in the crosstalk between the immune system and
the brain. It has been demonstrated that TNF- is able to
increase the expression of AMPA receptors and therefore
potentially strengthen the glutamatergic synapse [12].
However, the series of experimental studies on the role of
TNF- on synaptic plasticity yielded contradicting results.
While functional studies employing transgenic mouse mod-
els lacking TNFR1 and R2 receptors revealed normal syn-
aptic plasticity [130], Butler and colleagues [21] reported
inhibitory eVects of TNF- on LTP, thus suggesting that the
precise role of TNF- in the modulation of synaptic plastic-
ity is far more complex than initially thought. Altogether,
we can summarize here that up-regulation of major pro-
inXammatory cytokines after ischemia confers inhibition on
the early changes in the injury-induced synaptic plasticity.
It is important to mention however, that transcriptional acti-
vation for the genes encoding for above-mentioned cyto-
kines peaks at 12–24 h after ischemia [53, 79, 103] and
declines at the later time points. Hence, the direct inhibitory
eVects of pro-inXammatory cytokines on synaptic plasticity
should be evident within the Wrst 72 h after ischemia. At the
later time points after stroke (several days and weeks after
injuries), the role of pro-inXammatory cytokines in the
modulation of synaptic plasticity and thus potentially brain
plasticity/recovery is far less clear. One of the possibilities
is that pro-inXammatory cytokines may still be involved in
modulation of brain plasticity at the later time points via the
regulation of diVerent gene/protein expression. After ische-
mia, proteins such as growth associated protein-43 (GAP-
43), nestin, tubuline, peripherin, etc., that are normally
expressed in the developing brain and suppressed in the
adult CNS, become up-regulated [13, 27, 84, 96]. The
results of our previous studies demonstrated that peripherin,
one of developmentally highly expressed protein is strongly
up-regulated in CNS neurons after ischemia [13]. Periphe-
rin is a 57-kDa type III intermediate Wlament [112] and pre-
vious work suggests that is plays an important role in
neurite elongation during development [40]. In the adult,
peripherin is almost exclusively expressed in the neurons of
the peripheral nervous system (PNS), and in the CNS its
expression is limited to neurons with direct projections to
periphery [18, 109, 115], while normally it is undetectable
in most CNS neurons [13, 35]. Although at present the bio-
logical functions of peripherin are still poorly understood,
evidence suggests that in response to nerve injuries, peri-
pherin may be involved in neuronal regeneration. More
importantly, previous work using in vitro and in vivo model
systems revealed that peripherin expression can be induced
and modulated by pro-inXammatory cytokines such as IL-6
[13, 81, 131] and LIF [13, 35]. Functional analysis revealed
that up-regulation of peripherin has been associated with
the marked alterations in the synaptic plasticity in CA1 and
CA3 regions of the hippocampus [76]. These results may
provide evidence for a more direct involvement of the pro-
inXammatory cytokines in the brain remodeling and plastic-
ity. However, caution is required since persistent and
chronic induction of cytoskeletal proteins may lead to aber-
rant structural changes and pathological alterations in brain
plasticity [32, 66, 111]. For example, as shown in Fig. 1, a
chronic inXammatory response may lead to a pathological
expression of cytoskeletal proteins, such as peripherin, in
degenerating neurites surrounding amyloid plaques in the
mouse model of Alzheimer’s disease (Fig. 1). A question
here is whether these cytoskeletal alterations may in part
explain a known susceptibility of stroke patients to develop
Alzheimer’s type of dementia?
How brain inXammatory response to ischemic injury 
may aVect neurogenesis and brain recovery?
Pathological conditions such as cerebral ischemia can
strongly induce and/or promote adult neurogenesis [29, 61,
62, 73]. In speciWcally restricted areas of the mammalian
brain such as dentate gyrus of subventricular zone (SVZ),
the new functional neurons are generated from the endoge-
nous pools of neuronal stem cells throughout the life [91].
Following diVerent types of brain injuries including ische-
mia, the proliferative response is markedly increased in
these regions. Moreover, post-ischemia, new neurons could
be also found in the striatum and cerebral cortex, brain123
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sis [29, 61, 62, 73]. These Wndings strongly suggests that
pathological conditions may trigger the processes of endog-
enous neurogenesis in brain regions where adults neurogen-
esis is normally not existent. However, the functional
beneWts of such a response are presently a matter of numer-
ous debates. Furthermore, here it is important to mention
that these observations, in particular, with regard to newly
formed cortical neurons stem from rodents and have not
been conWrmed in humans.
A current view is that injury-induced neurogenesis may
carry a signiWcant impact on post-ischemic brain plasticity
and recovery. At present, the precise molecular mecha-
nisms involved in the induction and/or regulation of the
post-injury neurogenesis remain unknown. Mounting evi-
dence suggests that inXammation may play an important
role. By using two diVerent experimental approaches, the
initial work by Monje et al. [94] and Ekdahl et al. [37]
revealed that inXammation has a detrimental eVect on adult
brain neurogenesis, while Liu and colleagues [85] demon-
strated that long-term treatment with anti-inXammatory and
antimicrobial agent minocycline after stroke signiWcantly
increases the number of newborn neurons in the dentate
gyrus and improves functional recovery. New evidence,
however, suggest that the role of the inXammatory response
on adult neurogenesis is far more complex than initially
thought and may additionally depend on the direct interac-
tions between progenitors and activated glial cells [38]. It
has been demonstrated that following injuries, glial cells, in
particular microglia, depending on the activation state, can
adopt diVerent phenotypes (neurotoxic vs. neuroprotec-
tive). For instance, treatment of microglial cells with the
cytokine IL-4 would change the phenotype of activated
microglial from TNF- to IGF-1 producing cells [22]. We
observed similar Wndings following the treatment of acti-
vated microglial cells with MCSF [79]. Namely, changing
the state of microglial activation from highly-activated to
proliferating was associated with the signiWcant decrease in
TNF- production and the increase in IGF-1 secretion [79].
IGF-1 is a known anti-apoptotic factor and recent reports
suggest that it plays an important role in promotion of pro-
liferation and diVerentiation of neuronal progenitors [65,
107, 145]. Contrary to IGF-1, the studies performed on the
transgenic animals lacking TNFR1 revealed that TNFR1
acts as a negative regulator of neuronal progenitors in hip-
pocampus and in SVZ area after stroke [59, 60].
TLRs, response to ischemic injury and neurogenesis
To date, most of the studies exploring interactions between
inXammation, neuronal damage/neurogenesis and brain
plasticity have been focused on the role of diVerent pro-
inXammatory cytokines and trophic factors; however, rela-
tively little is known about the role and possible interac-
tions between the innate immune response, cerebral
ischemia, and brain recovery. The brain response to ische-
mia is characterized by a reactive microgliosis [33, 75, 77]
that is associated with a robust induction of the transmem-
brane receptor Toll-like receptor 2 (TLR2). While it has
been widely established that TLRs are the key mediators in
the response to invading pathogens, there is a growing line
of evidence suggesting that TLRs can be activated by
Fig. 1 Chronic inXammation is 
associated with the time and age-
dependent increase in peripherin 
expression in the brains of the 
mouse model of Alzheimer’s 
disease. Immunostaining with 
the anti-peripherin antibody 
(AB1530, 1:1,000 dilution, 
Chemicon) of the coronal brain 
sections revealed formation of 
the peripherin accumulations in 
degenerating neurites (black 
arrows) surrounding beta-
amyloid plaques (Congo red 
staining). The accumulations 
were detected only in older 
10-month-old transgenic mice 
(c, d), while the brains of the 
pre-symptomatic 5-month-old 
transgenic mice were devoid of 
plaques and peripherin 
immunoreactivities (a, b). 
Scale bars a, c = 500 m; 
c, d = 50 m123
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necrotic cells. More particularly, TLR2 and TLR4 can
interact with endogenous alarm signals such as heat shock
proteins (Hsp60 and 70), extracellular breakdown product
of hyaluron lipoproteins, etc., suggesting that TLRs may be
involved in the regulation of inXammatory response follow-
ing brain injuries [5, 47, 106] and neurodegeneration [99,
105]. Recent studies demonstrated that TLRs, in particular
TLR2 may be an important mediator of CNS ischemic
injury [83, 147]. The induction of TLR2 has been also
observed in the activated microglial cells in other types of
brain injuries. For example, TLR2 is strongly induced in
the microglial cells situated in denervated zones of the hip-
pocampus after following stereotaxic transsection of the
axons in the mouse entorhinal cortex [6]. Interestingly, in
the same experimental paradigm, the TLR2 deWciency in
mice was associated with an early delay in microglial pro-
liferation [6]. However, at present little is known about the
long-term role of TLR2 signaling and microglial activation
in the brain response to injury. The results of our recent
study revealed a very interesting and potentially long-term
role of TLR2 signaling and microglial activation in the
brain response to ischemic injury. Namely, taking advan-
tage of a mouse model recently developed in our laboratory
(TLR2 reporter mouse) in which we can longitudinally
visualize TLR2 induction/microglial activation, we
observed several very interesting primary Wndings [80].
First, the TLR2 response to cerebral ischemia was associ-
ated with a marked chronic component, which may last for
several months after initial stroke. Moreover, the inXamma-
tory response was not restricted to the site of injury being
also evident in the olfactory bulb (OB) [80]. As expected,
following ischemia, the TLR2 induction was predominately
observed in activated microglial cells. Another interesting
detail is that, in addition to activated glial cells the TLR2
immunoreactivity was also detected in the subset of double-
cortin (DCX) positive cells in OB as well as in the small
subset of stressed neurons situated with the center of ische-
mic lesion. These Wndings are in agreement with earlier
reports by Rolls et al. [117] where TLR2 expression was
detected in the cells expressing early neuronal markers such
as DCX. Moreover, TLR2 deWciency in mice was associ-
ated with signiWcantly impaired neurogenesis [117], thus
suggesting that TLR2 signaling may represent an important
link for cross dialog between injury-induced innate immune
response and brain neurogenesis/recovery.
However, the role of TLRs and in particular TLR2 in
brain ischemia is far from being elucidated. In the recent
work, Lehnardt et al. [83] and Ziegler et al. [147] reported
smaller infarction size in the mice lacking TLR2 receptors,
yet, on the other hand, the same signaling pathway has been
reported instrumental for brain neurogenesis [117]. From
the experimental results, it is conceivable that in acute
response to injuries activated microglial cells may play an
early detrimental role that can be converted into supportive
role in the later, chronic phase of the brain response to
ischemic injury. Supportive of that view are the results of
numerous pharmacological studies reporting neuroprotec-
tive eVects of the early anti-inXammatory treatments after
stroke. An additional example of time-dependent result dis-
crepancies in cerebral ischemia is the role of matrix metal-
loproteases (MMPs). While early inhibition of MMPs
conferred neuroprotection [4], data by Zhao and coworkers
[144] revealed that late inhibition of MMPs was associated
with an increase in the size ischemic injury and impaired
functional recovery; thus, again suggesting a time-depen-
dent nature and/or functional role of inXammatory response
in brain ischemia [1]. Therefore, to better understand the
temporal and the spatial dynamics of the post-ischemic
inXammation, there is a need to develop novel model sys-
tems. In our laboratory, we have developed an experimental
approach (in vivo bioluminescence and Xuorescence) to
longitudinally image and analyze astrocyte and microglial
responses from the brains of living animals following acute
injuries, such as ischemia, and in the model of chronic neu-
rodegenerative disorders [26, 68, 146]. Moreover, using
this imaging approach we were able to analyze glial
responses and a biocompatibility of several diVerent nano-
particles administered in the brain [89].
Live imaging: development of novel experimental 
approaches to study inXammation and brain recovery
In recent years, imaging strategies employing reporter mol-
ecules have been developed to study biological processes as
they occur in living animals or as they appear in real time in
cell assays. These new technologies are based on sources of
light emitted from Xuorescent proteins or luminescent
enzymes. One class of reporter genes that have been used
for in vivo detection is Xuorescent protein such as GFP. For
example, Pan et al. [108] reported the in vivo visualization
of axons in transgenic mice expressing a Thy-1 promoter/
GFP construct. Another approach uses bioluminescence
enzymes like the WreXy luciferase (Fluc) that emits light
when provided with the appropriate substrate [25, 36]. Bio-
luminescence is a chemical reaction and no external excita-
tion is needed to obtain the signal. Luciferase catalyzes the
cleavage of the substrate luciferin in presence of oxygen
and ATP, resulting in the emission of light with broad spec-
tral emission that peaks at 560 nm with substantial fraction
of light above 600 nm making it suitable for in vivo imag-
ing. The photons emitted by Fluc reporter activity pass the
host tissue and are detectable at the surface with sensitive
photo detectors based on a CCD camera (see Fig. 2). The
bioluminescence produces a better signal-to-noise ratio123
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with no background of light emission from rodent tissues
and luciferin is non-toxic. However, the in vivo biolumi-
nescence and whole animal imaging is not without the pit-
falls. One major weaknesses of this approach is the
relatively low signal-to-signal resolution. Further, during in
vivo imaging, the experimental animals are shortly anesthe-
tised (for few minutes) which can inXuence neuronal activ-
ity. In addition, because the imaging protocols and the
acquisition of the bioluminescent images may last for
several minutes, (in general 1–3 min), this method is not
suitable for in vivo imaging of the fast cellular and the
metabolic changes. An alternative approach is in vivo high
resolution optical imaging and multiphoton microscopy
[92]. This technique has a far superior microscopic resolu-
tion; however, a major weakness of this approach is the
relatively low tissue penetration (»500 m) that limits the
imaging of the brain after ischemia to the examination of
the cerebral cortex [72, 123].
Keeping in mind advantages and disadvantages of diVer-
ent in vivo optical imaging approaches, we have developed
and validated in a stroke model several transgenic mouse
model of bioluminescence and Xuorescence for time-lapse
imaging of processes associated with CNS neuroinXamma-
tion, in particular, microglia [80] and astrocyte activation
[26, 68, 146]. To investigate the TLR2 response and associ-
ated microglial activation in the living brain, we generated
a transgenic mouse model bearing the dual reporter system
luciferase and green Xuorescent protein (GFP) under the
transcriptional control of a murine TLR2 promoter. In this
mouse model, transcriptional activation of TLR2 (biolumi-
nescence photon emission) can be visualized in the brains
of live animals using biophotonic/bioluminescence imaging
and high resolution CCD camera (Figs. 2, 3) [80]. After
experimental stroke, we were able to image and analyze the
innate immune response and microglial activation from the
same living mouse over a 3–4 month time-period (see
Fig. 3).The advantage of a dual reporter system is that fol-
lowing in vivo bioluminescence imaging in the same ani-
mal using GFP as a reporter, we can analyze the same
subpopulation of the cells (activated microglia) using
microscopic resolution [80]. Because inXammation after
stroke is a dynamic process with an important spatial as
well as temporal component, it is our view, that these
mouse models will provide unique tools for additional
understanding of disease pathology and brain response to
ischemic injury and can be very valuable in longitudinal
responses to drug testing.
Conclusion
In conclusion, in the presented work, we sought to discuss
how post-ischemic inXammation may aVect brain plasticity.
The answer to this question is rather complex and it is
beyond the scope of just one review. As described, evi-
dence suggests that post-ischemic inXammation contributes
to brain injury and to the expansion of the ischemic lesion.
On the other hand, adequate immune response after injuries
Fig. 2 Schematic representation of in vivo biophotonic/biolumines-
cence imaging from the brains of transgenic reporter mice
Fig. 3 Representative photographs of single transgenic TLR2-luc/gfp
reporter mouse imaged at diVerent time points following 1-h transient
MCAO. Real-time imaging of TLR2 response/microglial activation
reveals a long-term induction of inXammatory signals (up to 3-months
post-ischemia). Photographs show diVerent sites of TLR2 induction in
the brain: one in a frontal area and one at the site of the ischemic lesion.
The color calibrations at the right are photon counts. Note the occur-
rence of diVerent scales in various ranges123
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repair suggesting that the role of inXammation in the brain
response to ischemic injury goes beyond simple good-ver-
sus-bad dichotomy (see Fig. 4). It is our hope that novel
experimental approaches (and novel animal models) such
as in vivo biophotonic/bioluminescence imaging will pro-
vide a novel knowledge on the complex spatial and tempo-
ral nature of the inXammatory response in the brain.
Finally, development of novel in vivo imaging tools may
facilitate development of new therapeutic strategies for
stroke patients.
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